文献速递基础与转化研究新药、器械与细胞基因治疗研发

转录后基因沉默BCL11A治疗镰状细胞病

Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease.
PubMed 文献 · N Engl J Med · 2020-12-05

单中心开放标签先导研究纳入6例镰状细胞病患者,输注经BCH-BB694慢病毒载体转导的自体CD34+细胞,该载体携带靶向BCL11A mRNA的shRNA(嵌入microRNA的shmiR),实现红系特异性敲低。所有可评估患者均实现稳健稳定的HbF诱导,随访期间镰状细胞病临床表现减少或消失。

要点

  • BCL11A抑制可有效诱导HbF,为镰状细胞病治疗靶点
  • shmiR介导的基因敲低在该先导研究中显示有利的风险-获益特征
  • 所有可完全评估患者达到稳健稳定HbF诱导,临床表现减少或消失

核心结论

  • 本研究验证BCL11A抑制是诱导HbF的有效靶点,并初步表明基于shmiR的基因敲低在镰状细胞病中具有有利的风险-获益特征。

研究设计与样本

  • 单中心、开放标签先导研究,纳入镰状细胞病患者,输注经BCH-BB694慢病毒载体转导的自体CD34+细胞。
  • 主要终点为植入与安全性,同时评估血液学与临床反应。

主要发现

  • 全部患者均实现植入,不良事件与预处理化疗效应一致。
  • 所有可完全评估患者实现稳健稳定HbF诱导,最近随访HbF/(F+S)百分比为20.4%至41.3%。
  • HbF广泛分布于红细胞,未输血红细胞中F细胞占58.9%至93.6%,每个F细胞HbF为9.0至18.6 pg。
  • 随访期间镰状细胞病临床表现减少或消失。

临床怎么用

  • 该先导研究支持BCL11A抑制作为诱导HbF的有效靶点,为镰状细胞病基因治疗提供初步依据。

局限性

  • 单中心、开放标签先导研究,样本量小(6例),随访时间有限,结论需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sickle cell disease is characterized by hemolytic anemia, pain, and progressive organ damage. A high level of erythrocyte fetal hemoglobin (HbF) comprising α- and γ-globins may ameliorate these manifestations by mitigating sickle hemoglobin polymerization and erythrocyte sickling. BCL11A is a repressor of γ-globin expression and HbF production in adult erythrocytes. Its down-regulation is a promising therapeutic strategy for induction of HbF. METHODS: We enrolled patients with sickle cell disease in a single-center, open-label pilot study. The investigational therapy involved infusion of autologous CD34+ cells transduced with the BCH-BB694 lentiviral vector, which encodes a short hairpin RNA (shRNA) targeting BCL11A mRNA embedded in a microRNA (shmiR), allowing erythroid lineage-specific knockdown. Patients were assessed for primary end points of engraftment and safety and for hematologic and clinical responses to treatment. RESULTS: As of October 2020, six patients had been followed for at least 6 months after receiving BCH-BB694 gene therapy; median follow-up was 18 months (range, 7 to 29). All patients had engraftment, and adverse events were consistent with effects of the preparative chemotherapy. All the patients who could be fully evaluated achieved robust and stable HbF induction (percentage HbF/(F+S) at most recent follow-up, 20.4 to 41.3%), with HbF broadly distributed in red cells (F-cells 58.9 to 93.6% of untransfused red cells) and HbF per F-cell of 9.0 to 18.6 pg per cell. Clinical manifestations of sickle cell disease were reduced or absent during the follow-up period. CONCLUSIONS: This study validates BCL11A inhibition as an effective target for HbF induction and provides preliminary evidence that shmiR-based gene knockdown offers a favorable risk-benefit profile in sickle cell disease. (Funded by the National Institutes of Health; ClinicalTrials.gov number, NCT03282656).

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Esrick EB, Lehmann LE, Biffi A, et al. Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease. N Engl J Med. 2020. PMID: 33283990. doi:10.1056/NEJMoa2029392

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。